http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24351769

Outgoing Links

Predicate Object
contentType Journal Article|Published Erratum
issn 1932-6203
issueIdentifier 8
pageRange e0202709-
publicationName PLOS ONE
startingPage e0202709
bibliographicCitation Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE. 2018 Aug 15;13(8):e0202709. doi: 10.1371/journal.pone.0202709.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e12ba7f2480396c08817594f197833ce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa98d3c8461b8abaa05d082c8b421a50
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4706233bb29de9717840e2ae3710a813
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e168ffd2d31a55fa9a9b7e2ea672593a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81799b5f1db4858f4ed9253b51b9599f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa59322d01d81379f2768ee953d94385
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_564f5b65e03b6143ce2f1564b7da6192
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec90f85d71572f6a7e9211d4380e3196
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8e7d588c38d1af755f947dd965a5128
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8c1a5ecaf7fee48ac016600ebb20772
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_503ef67d7814def4d29629547d0393b6
date 2018-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1371/journal.pone.0202709
https://pubmed.ncbi.nlm.nih.gov/30110398
https://pubmed.ncbi.nlm.nih.gov/PMC6093693
isPartOf https://portal.issn.org/resource/ISSN/1932-6203
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33103
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15951529
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4477
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983

Total number of triples: 32.